Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)’s share price was up 16.3% during trading on Monday . The company traded as high as $1.71 and last traded at $1.71. Approximately 513,262 shares were traded during trading, a decline of 55% from the average daily volume of 1,131,499 shares. The stock had previously closed at $1.47.

Separately, ValuEngine upgraded shares of Titan Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, February 2nd.

The company has a current ratio of 3.85, a quick ratio of 3.49 and a debt-to-equity ratio of 0.55. The firm has a market cap of $19.71 million, a PE ratio of -2.16 and a beta of 0.70.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings results on Monday, April 1st. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.20). The company had revenue of $1.24 million during the quarter, compared to analysts’ expectations of $0.40 million. Titan Pharmaceuticals had a negative net margin of 136.32% and a negative return on equity of 355.20%. Analysts expect that Titan Pharmaceuticals, Inc. will post -0.59 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc grew its stake in Titan Pharmaceuticals by 12.7% in the 3rd quarter. Vanguard Group Inc now owns 432,337 shares of the specialty pharmaceutical company’s stock valued at $90,000 after acquiring an additional 48,760 shares during the last quarter. Virtu Financial LLC grew its stake in Titan Pharmaceuticals by 530.0% in the 4th quarter. Virtu Financial LLC now owns 236,182 shares of the specialty pharmaceutical company’s stock valued at $53,000 after acquiring an additional 198,693 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Titan Pharmaceuticals by 256.0% in the 4th quarter. Geode Capital Management LLC now owns 341,474 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 245,565 shares during the last quarter. Institutional investors and hedge funds own 30.49% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2019/04/15/titan-pharmaceuticals-ttnp-trading-up-16-3.html.

About Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

See Also: What is Cost of Goods Sold (COGS)?

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.